Literature DB >> 16942537

Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire.

Andrew T Goldstein1, Daisy Klingman2, Kurt Christopher3, Crista Johnson4, Stanley C Marinoff5.   

Abstract

INTRODUCTION: Vulvar vestibulitis syndrome (VVS) is the most common pathology in women with sexual pain. Surgery for VVS was first described in 1981. Despite apparently high surgical success rates, most review articles suggest that surgery should be used only "as a last resort." Risks of complications such as bleeding, scarring, and recurrence of symptoms are often used to justify these cautionary statements. However, there are little data in the peer-reviewed literature to justify this cautionary statement. AIMS: To determine patient satisfaction with vulvar vestibulectomy for VVS and the rate of complications with this procedure.
METHODS: Women who underwent a complete vulvar vestibulectomy with vaginal advancement by one of three different surgeons were contacted via telephone by an independent researcher between 12 and 72 months after surgery. MAIN OUTCOME MEASURES: The primary outcome measurement of surgical success was overall patient satisfaction with surgery. Additional secondary outcome measurements included improvement in dyspareunia, changes in coital frequency, and occurrence of surgical complications.
RESULTS: In total, 134 women underwent surgery in a 5-year period. An independent research assistant was able to contact 106 women, and 104 agreed to participate in the study. Mean duration since surgery was 26 months. A total of 97 women (93%) were satisfied, or very satisfied, with the outcome of their surgery. Only three patients (3%) reported persistently worse symptoms after surgery and only seven (7%) reported permanent recurrence of any symptoms after surgery. Prior to surgery, 72% of the women were completely apareunic; however, after surgery, only 11% were unable to have intercourse. DISCUSSION: In this cohort of patients, there was a high degree of satisfaction with surgery for VVS. In addition, the risks of complications with this procedure were low, and most complications were transient and the risk of recurrence after surgery was also found to be low.

Entities:  

Mesh:

Year:  2006        PMID: 16942537     DOI: 10.1111/j.1743-6109.2006.00303.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  7 in total

Review 1.  A practical guide to female sexual dysfunction: An evidence-based review for physicians in Canada.

Authors:  Yonah Krakowsky; Ethan D Grober
Journal:  Can Urol Assoc J       Date:  2018-02-23       Impact factor: 1.862

Review 2.  Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches.

Authors:  Natalie O Rosen; Samantha J Dawson; Melissa Brooks; Susan Kellogg-Spadt
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

Review 3.  A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review.

Authors:  Holly N Thomas; Rebecca C Thurston
Journal:  Maturitas       Date:  2016-02-21       Impact factor: 4.342

Review 4.  Vulvodynia.

Authors:  Sophie Bergeron; Barbara D Reed; Ursula Wesselmann; Nina Bohm-Starke
Journal:  Nat Rev Dis Primers       Date:  2020-04-30       Impact factor: 52.329

Review 5.  New Insights about Chronic Pelvic Pain Syndrome (CPPS).

Authors:  Keren Grinberg; Yael Sela; Rachel Nissanholtz-Gannot
Journal:  Int J Environ Res Public Health       Date:  2020-04-26       Impact factor: 3.390

6.  Patient Satisfaction of Surgical Treatment of Clitoral Phimosis and Labial Adhesions Caused by Lichen Sclerosus.

Authors:  Anne N Flynn; Michelle King; Mollie Rieff; Jill Krapf; Andrew T Goldstein
Journal:  Sex Med       Date:  2015-11-13       Impact factor: 2.491

7.  Treatment of Provoked Vulvodynia in a Swedish cohort using desensitization exercises and cognitive behavioral therapy.

Authors:  Suzanne Lindström; Linda J Kvist
Journal:  BMC Womens Health       Date:  2015-11-25       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.